ENDPOINTS

FDA approves Satsuma's migraine nasal spray after rejection in 2024

The FDA approved a new nasal spray for migraines that was developed by Satsuma Pharmaceuticals. Previously called STS101, the company said Wednesday that the drug's brand name is Atzumi and is ...

May 1, 2025 - 15:56
 0
FDA approves Satsuma's migraine nasal spray after rejection in 2024
The FDA approved a new nasal spray for migraines that was developed by Satsuma Pharmaceuticals. Previously called STS101, the company said Wednesday that the drug's brand name is Atzumi and is ...
Read More

Tags:

Previous Article

Plenful scores $50M and more funding news

Next Article

Talkspace, Bark Technologies partner to monitor children's online activities

Related Posts

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

Thermo Fisher buckles up for US-China trade war, budget...

Apr 24, 2025  0

Updated: Roche’s $50B US investment includes previous build announcements

Updated: Roche’s $50B US investment includes previous b...

Apr 22, 2025  0

GSK's supply chain 'reset' after Haleon spinoff to ease tariff impact, CEO says

GSK's supply chain 'reset' after Haleon spinoff to ease...

Apr 30, 2025  0